Charles R. Kummeth - 17 Jun 2021 Form 4 Insider Report for BIO-TECHNE Corp (TECH)

Role
Chief Executive Officer, Director
Signature
/s/ Brenda S. Furlow as Attorney-in-Fact for Charles R. Kummeth pursuant to Power of Attorney previously filed.
Issuer symbol
TECH
Transactions as of
17 Jun 2021
Net transactions value
-$5,620,006
Form type
4
Filing time
21 Jun 2021, 16:36:53 UTC
Previous filing
16 Jun 2021
Next filing
10 Aug 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TECH Common Stock Sale $3,025,024 -6,732 -4% $449.35* 160,172 17 Jun 2021 Direct F1, F2, F3
transaction TECH Common Stock Sale $764,762 -1,698 -1.1% $450.39* 158,474 17 Jun 2021 Direct F1, F3, F4
transaction TECH Common Stock Sale $474,117 -1,050 -0.66% $451.54* 157,424 17 Jun 2021 Direct F1, F3, F5
transaction TECH Common Stock Sale $49,282 -109 -0.07% $452.13* 157,315 17 Jun 2021 Direct F1, F3
transaction TECH Common Stock Sale $1,159,999 -2,583 -1.6% $449.09* 154,732 18 Jun 2021 Direct F1, F3, F6
transaction TECH Common Stock Sale $146,821 -326 -0.21% $450.37* 154,406 18 Jun 2021 Direct F1, F3, F7
holding TECH Common Stock 100 17 Jun 2021 By Step-Son
holding TECH Common Stock 100 17 Jun 2021 By Step-Daughter

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TECH Stock Options (Right to Buy) 95,346 17 Jun 2021 Common Stock 95,346 $108.49 Direct F8
holding TECH Stock Options (Right to Buy) 79,517 17 Jun 2021 Common Stock 79,517 $108.49 Direct F8
holding TECH Stock Options (Right to Buy) 154,169 17 Jun 2021 Common Stock 154,169 $106.59 Direct F8
holding TECH Stock Options (Right to Buy) 102,779 17 Jun 2021 Common Stock 102,779 $106.59 Direct F8
holding TECH Stock Options (Right to Buy) 117,342 17 Jun 2021 Common Stock 117,342 $125.05 Direct F8
holding TECH Stock Options (Right to Buy) 78,228 17 Jun 2021 Common Stock 78,228 $125.05 Direct F10
holding TECH Restricted Stock Units 16,918 17 Jun 2021 Common Stock 16,918 Direct F9, F11
holding TECH Stock Options (Right to Buy) 90,334 17 Jun 2021 Common Stock 90,334 $177.32 Direct F11
holding TECH Stock Options (Right to Buy) 60,222 17 Jun 2021 Common Stock 60,222 $177.32 Direct F12
holding TECH Restricted Stock Units 16,937 17 Jun 2021 Common Stock 16,937 Direct F9, F13
holding TECH Stock Options (Right to Buy) 85,725 17 Jun 2021 Common Stock 85,725 $190.41 Direct F13
holding TECH Stock Options (Right to Buy) 57,150 17 Jun 2021 Common Stock 57,150 $190.41 Direct F14
holding TECH Restricted Stock Units 12,879 17 Jun 2021 Common Stock 12,879 Direct F9, F15
holding TECH Stock Options (Right to Buy) 57,442 17 Jun 2021 Common Stock 57,442 $267.87 Direct F15
holding TECH Stock Options (Right to Buy) 38,295 17 Jun 2021 Common Stock 38,295 $267.87 Direct F16
holding TECH Stock Options (Right to Buy) 16,650 17 Jun 2021 Common Stock 16,650 $267.87 Direct F17
holding TECH Stock Options (Right to Buy) 16,650 17 Jun 2021 Common Stock 16,650 $267.87 Direct F18
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 18, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $449.00 to $449.94, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 Includes (i) 3,759 shares of restricted stock for which the risk of forfeiture will lapse on August 8, 2021; (ii) 7,527 shares of restricted stock for which the risk of forfeiture will lapse with respect to 3,764 shares on August 7, 2021 and as to 3,763 shares on August 7, 2022; and (iii) 8,586 shares of restricted stock for which the risk of forfeiture will lapse as to 2,862 shares on each of August 5, 2021, August 5, 2022 and August 5, 2023.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $450.075 to $450.95, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $451.02 to $452.02, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $449.00 to $449.63, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $450.37 to $450.625, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F8 Fully exercisable.
F9 Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F10 Options to purchase 19,557 shares vest on each of 8/9/2018, 8/9/2019, 8/9/2020 and 8/9/2021.
F11 Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F12 Options to purchase 15,056 shares vest on each of 8/8/2019 and 8/8/2020 and options to purchase 15,055 shares vest on each of 8/8/2021 and 8/8/2022.
F13 Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F14 Options to purchase 14,288 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 14,287 shares vest on each of 8/7/2022 and 8/7/2023.
F15 Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F16 Options to purchase 9,573 shares vest on 8/5/21 and options to purchase 9,574 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.
F17 Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
F18 Options to purchase 5,550 shares vest on each of 8/5/21, 8/5/22 and 8/5/23.